Fennec to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York on September 10, 2015
Marketwired - Thu Sep 03, 6:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City at 5:05 EDT on Thursday, September 10, 2015. The conference is being held at the St. Regis Hotel in New York City.
FRX.TO: 2.63 (-0.06)
Fennec Provides Corporate Update and Announces Second Quarter 2015 Financial Results
Marketwired - Tue Aug 11, 4:01PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the second quarter ended June 30, 2015.
FRX.TO: 2.63 (-0.06)
Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting
PR Newswire - Mon Jun 01, 10:00AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.63 (-0.06)
Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting
Marketwired - Sun May 31, 8:01PM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX) (OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.63 (-0.06)
Fennec to Present at the Jefferies 2015 Global Healthcare Conference
Marketwired - Fri May 29, 5:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overview of the Company's business on Tuesday, June 2, 2015 at 11:30 a.m. (ET).
FRX.TO: 2.63 (-0.06)
Fennec Announces Results of Annual Meeting
Marketwired - Thu May 28, 7:29PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the "Circular"
FRX.TO: 2.63 (-0.06)
Fennec Provides Corporate Update and First Quarter Ended March 31, 2015 Financial Results
Marketwired - Fri May 15, 6:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate developments and financial results for the first quarter ended March 31, 2015.
FRX.TO: 2.63 (-0.06)
Fennec Announces Availability of Siopel 6 Study Abstract for ASCO 2015 Meeting
Marketwired - Thu May 14, 5:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." at the American Society of Clinical Oncology (ASCO) being held May 29 through June 2, 2014 in Chicago, IL. The abstract is available as of today on the website http://www.abstract.asco.org/.
FRX.TO: 2.63 (-0.06)
Fennec Pharmaceuticals Announces the Exercise of Warrants by the Company's Largest Shareholder and Provides Updated Corporate Capital Structure
Marketwire Canada - Mon May 04, 6:17AM CDT
Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today reported that Southpoint Master Fund, LP ("Southpoint"
FRX.TO: 2.63 (-0.06)
Southpoint Files Early Warning Report in Connection With Exercise of Warrants in Fennec Pharmaceuticals Inc.
Marketwired - Wed Apr 29, 12:32PM CDT
Southpoint Master Fund, LP ("Southpoint"
Fennec Pharmaceuticals Provides Corporate Update and Fiscal Year Ended December 31, 2014 Financial Results
Marketwired - Wed Apr 01, 6:31AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 2.63 (-0.06)